ERBB4 promoter polymorphism is associated with poor distant disease-free survival in high-risk early breast cancer

Keyphrases

• ErbB4 100%
• High-risk Early Breast Cancer 100%
• Promoter Polymorphism 100%
• Distant Metastasis-free Survival 100%
• Breast Cancer 20%
• Kinase Domain mutations 20%
• Prognostic Significance 20%
• Growth in Vitro 10%
• Breast Cancer Patients 10%
• Genotype 10%
• Poor Survival 10%
• Promoter Region 10%
• Kaplan-Meier 10%
• FinHer 10%
• Cox Regression Analysis 10%
• Cancer Clinical Trials 10%
• Germ Cells 10%
• Well-differentiated 10%
• DNA Samples 10%
• Clinical Material 10%
• Somatic mutation 10%
• Prognostic Marker 10%
• Cancer Cell Growth 10%
• Genetic Variants 10%
• Hereditary Factors 10%
• Paraffin Embedding 10%
• Tumor DNA 10%
• Matrix-assisted Laser Desorption Ionization-time of Flight Mass Spectrometry (MALDI-TOF MS) 10%
• Breast Cancer Risk 10%
• Tumor Section 10%

Medicine and Dentistry

• Promoter Region 100%
• Breast Cancer 100%
• Disease Free Survival 100%
• Neoplasm 33%
• Phosphotransferase 33%
• Somatics 33%
• Malignant Neoplasm 16%
• In Vitro 16%
• Cancer Growth 16%
• Proportional Hazards Model 16%
• Matrix Assisted Laser Desorption Ionization Time of Flight Mass Spectrometry 16%
• Germ Line 16%
• Somatic Mutation 16%
• Germ Cell 16%

Biochemistry, Genetics and Molecular Biology

• Promoter Region 100%
• ERBB4 100%
• Disease Free Survival 100%
• Genotyping 22%
• Kinase 22%
• Phosphotransferase 22%
• Cell Growth 11%
• Cancer Cell 11%
• Genetic Divergence 11%
• Germ Cell 11%
• Matrix-Assisted Laser Desorption/Ionization 11%
• Somatic Mutation 11%
• Time-of-Flight Mass Spectrometry 11%